skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

60 Total results for product and free and sample content found

Generics Bulletin

India Biosimilars Landscape

12 Oct 2021

India Biosimilars Landscape

India leads the ways with the highest number of approved biosimilars.

Topic Clinical Trials Biosimilars

Generics Bulletin

Informa’s Global Generics & Biosimilars Awards Slated for Milan, Italy This Summer

05 Mar 2021

Informa’s Global Generics & Biosimilars Awards Slated for Milan, Italy This Summer

London – 5 March, 2021 – Planning is underway for the 2021 Global Generics & Biosimilars Awards. The awards, now in their eighth year, celebrate successes across the generics, biosimilars, and value-added medicines industries. 

Topic Biosimilars Press Release

Generics Bulletin

Coherus Is Confident After US Ranibizumab Filing

By Aidan Fry 27 Nov 2020

Coherus_Is_Confident_After_US

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Topic Biosimilars Deals

Generics Bulletin

Celltrion's Remsima SC Ready For Early 2020 Launch

By David Wallace 27 Nov 2020

Article

Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.

Topic Biosimilars Launches Regulation

Datamonitor Healthcare

The evolving landscape of biosimilars

27 Nov 2020

The evolving landscape of biosimilars

It is important to understand how the biosimilar market has developed over the past five years. Take a look at some of the key events here.

Topic Biosimilars

Generics Bulletin

Alberta Is Second Canadian Province To Switch To Biosimilars

By David Wallace 27 Nov 2020

Alberta_Is_Second_Canadian_Province_To_Switch_1

Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

Topic Biosimilars Regulation

Generics Bulletin

Pfizer Reports 80% Biosimilars Growth In Q3

By Akriti Seth 17 Nov 2020

pfizer biosimilars growth

Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.

Topic Coronavirus Biosimilars Deals

Pink Sheet

Germany Sets Direction Of Travel With New Biosimilar Guidelines

By Francesca Bruce 21 Sep 2020

Biosimilars Germany

Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in move towards increasing biosimilar uptake.

Topic EU Biosimilars

Chemist + Druggist Data

UK Sees PIP Codes Expand To Cover Hospital Drugs

By C+D Data 09 Sep 2020

Pharmacists PIP Code Expansion

Chemist + Druggist has expanded its “PIP code” system for UK pharmacy procurement to also encompass hospital drugs.

Topic BioPharmaceutical Regulation Biosimilars

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: